Cobenfy, a combination of xanomeline and trospium chloride, was approved in the US in 2024 for the treatment of schizophrenia. The drug is now being investigated in several Phase 3 trials as a treatment for patients with psychosis associated with Alzheimer's disease. One trial is assessing the initial treatment response, while another primarily examines the long-term safety and tolerability of the treatment.
Schizophrenia drug shows promise in Alzheimer’s psychosis
A schizophrenia drug from Bristol Myers Squibb has shown promising results against psychotic symptoms in patients with Alzheimer's disease in two Phase 3 trials.
Advertisement